Transcription Factors in B cells as Targets for Therapeutic Modulation in SLE

Background:

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of harmful autoantibodies from self-reactive B cells and plasma cells. Current treatments often lack precision, indiscriminately suppressing the immune system and causing adverse effects. The need for targeted therapies that eliminate only the autoreactive cells while preserving protective immune functions has driven research into the underlying molecular mechanisms governing B cell tolerance. This technology builds on findings that certain transcription factors within the MIT family regulate the survival and activity of self-reactive B cells, providing a new pathway for therapeutic intervention.

Technology Overview:

This innovation centers on targeting the MIT family of transcription factors, particularly Mitf and TFEC, which play crucial roles in B cell function related to autoimmune disease progression. Mitf functions as a protective factor by promoting the elimination of self-reactive B cells and plasma cells that produce pathogenic autoantibodies. Conversely, TFEC may interfere with Mitf’s role, potentially allowing autoreactive cells to survive and exacerbate SLE. The proposed technology leverages this understanding by selectively modulating these transcription factors to restore immune tolerance. By enhancing Mitf activity or inhibiting TFEC, the treatment strategy aims to prevent the formation and survival of harmful autoreactive B cells without suppressing the overall immune system. This targeted approach is a significant advancement over existing therapies because it offers precision in controlling pathological immune responses while minimizing side effects. Patent claims cover broad regulatory methods and specific techniques for influencing MIT family transcription factors, positioning this technology as a versatile platform for developing future autoimmune disease treatments. The underlying science not only improves the specificity of therapeutic interventions but also opens new avenues for research into immune regulation at the genetic and molecular levels.

Advantages:

•    Selective targeting of autoreactive B cells reduces off-target effects commonly seen in broad immunosuppressive therapies.
•    Modulating transcription factors offers a novel mechanism to restore immune tolerance at the cellular level.
•    Potential to prevent disease progression by enhancing natural protective pathways inherent in B cell regulation.
•    Broad patent protection enables diverse treatment strategies targeting the MIT family of transcription factors.
•    Reduces risk of compromising overall immune function, improving patient safety and treatment outcomes.

Applications:

•    Therapeutic development for systemic lupus erythematosus (SLE) and other autoimmune diseases involving pathological B cells.
•    Targeted modulation of B cell activity in immunology research and drug discovery.
•    Personalized medicine approaches for patients with autoreactive B cell disorders.
•    Potential use as a platform technology for regulating transcription factors in various immune-related conditions.

Intellectual Property Summary:

Patent application filed, 19/038,490
https://patents.google.com/patent/US20250241984A1/en

Stage of Development:

TRL 3 – Experimental Proof of Concept

Licensing Status:

This technology is available for licensing.